Metro . The key comments by bioshares are as follows.
1.The fda approval for axiron represents an outstanding achievement for the australian biotech industry.
2.The market opportunity for axiron is significant from several points of view.
3.Dividend could be announced at tomorrow agm.Bioshares believe the company could comfortably return 50 cents per share tax free.
bioshare report/simply magnificent acrux
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.89M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3903 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.4¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable